First-line EGFR-TKIs Treatment In Patients With Postoperative Intrapulmonary Recurrent Stage I Non-small-cell Lung Cancer Harboring EGFR Gene Mutations

Background:The epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor(TKI)is an effective treatment for advanced lung cancer harboring EGFR gene mutations,and has improved progression-free survival in several clinical trials.Methods:We investigated 22 patients with postoperative intrapulmonary recurrent stage I non-small-cell lung cancer harboring EGFR gene mutations.Progression-free survival and response rate were analyzed.Results:Partial response was achieved in 17 patients and stable disease was found in 5 patients.The objective response rate was 77.3%and disease control rate was 100%.The median progression-free survival(PFS)time was 16.5 months.The median PFS in patients with only intrapulmonary recurrent was significantly superior to patients with both intrapulmonary recurrent and metastasis(17 months vs 10 months,p=0.017).There was no statistical difference in median PFS between those age<65 and>65,male and female,smoker and non-smoker,EGFR 19 gene deletion and EGFR 21 gene mutation,different T stages,different resection of lung lobes or received gefitinib and received icotinib.Conclusion:Our results reveals that first-line EGFR-TKIs treatment for stage I non-small-cell lung cancer harboring EGFR gene mutations with postoperative intrapulmonary recurrent is effective and could be a useful option in practical setting.